GYRE has been in the news 346% more than usual
Jun 10, 2025, 2:34 PM
-10.06%
What does GYRE do
Gyre Therapeutics, a San Diego-based biopharmaceutical company with 593 employees, focuses on developing F351 for treating NASH-associated fibrosis and has a pipeline through its indirect interest in Gyre Pharmaceuticals. The company went public on April 12, 2006, and also offers the drug ETUARY.
GYRE has been in the news recently: GYRE THERAPEUTICS is not directly mentioned in the provided information, but it is important to note that Anixa Biosciences will present a Phase 1 clinical trial of its ovarian cancer CAR-T therapy at the ESMO Congress in June 2025. Additionally, Elevation Oncology, Inc. is set to be acquired by Concentra Biosciences for $0.36 per share, with the merger expected to close in July 2025.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.